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Platelet/granulocyte aggregates (PGAs) increase thromboinflammation in the vascula-
ture, and PGA formation is tightly controlled by the complement alternative pathway (AP) 
negative regulator, Factor H (FH). Mutations in FH are associated with the prothrombotic 
disease atypical hemolytic uremic syndrome (aHUS), yet it is unknown whether increased 
PGA formation contributes to the thrombosis seen in patients with aHUS. Here, flow 
cytometry assays were used to evaluate the effects of aHUS-related mutations on FH 
regulation of PGA formation and characterize the mechanism. Utilizing recombinant 
fragments of FH spanning the entire length of the protein, we mapped the regions of 
FH most critical for limiting AP activity on the surface of isolated human platelets and 
neutrophils, as well as the regions most critical for regulating PGA formation in human 
whole blood stimulated with thrombin receptor-activating peptide (TRAP). FH domains 
19–20 were the most critical for limiting AP activity on platelets, neutrophils, and at 
the platelet/granulocyte interface. The role of FH in PGA formation was attributed to its 
ability to regulate AP-mediated C5a generation. AHUS-related mutations in domains 
19–20 caused differential effects on control of PGA formation and AP activity on platelets 
and neutrophils. Our data indicate FH C-terminal domains are key for regulating PGA 
formation, thus increased FH protection may have a beneficial impact on diseases 
characterized by increased PGA formation, such as cardiovascular disease. Additionally, 
aHUS-related mutations in domains 19–20 have varying effects on control of TRAP-
mediated PGA formation, suggesting that some, but not all, aHUS-related mutations 
may cause increased PGA formation that contributes to excessive thrombosis in patients 
with aHUS.
Keywords: factor h, platelet, neutrophil, complement, atypical hemolytic uremic syndrome
inTrODUcTiOn
The complement alternative pathway (AP) is a key component of the innate immune system. Not 
only does it maintain a low level of spontaneous activity in the fluid phase but it also amplifies 
complement activity initiated by the classical and lectin pathways. C3b deposited on cell surfaces by 
any complement pathway acts as a locus for AP activation. Factor B binds C3b and is subsequently 
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cleaved by Factor D to form the C3 convertase, C3bBb. C3bBb 
cleaves more C3 to C3b that can bind covalently to cells and 
recruit Factor B to form additional AP C3 convertases. C3b 
bound, or in close proximity, to C3bBb [C3bBb(C3b)n] switches 
the specificity of the enzymatic complex from C3 to C5, leading 
to terminal complement activation that generates the effector 
molecules C5a and the membrane attack complex (MAC). Due 
to its spontaneity and its ability to amplify all complement activ-
ity, the human host has developed many regulatory mechanisms 
to prevent excessive AP activation (1).
Factor H (FH) is the key regulator of the AP in the fluid 
phase and also functions to limit AP activity selectively on self-
cell surfaces (2). It accelerates the decay of C3/C5 convertases, 
and acts as a cofactor for Factor I-mediated cleavage of C3b to 
inactive C3b (iC3b) to prevent further convertase formation (3, 
4). Twenty homologous complement control protein domains 
comprise FH. The four most N-terminal domains (domains 
1–4) contain all of the protein’s regulatory function, whereas 
the remaining domains help anchor the protein to cell surfaces 
for efficient regulation by domains 1–4 (2). At least two distinct 
C3b and polyanion binding sites have been described between 
domains 7–20 (5). While these binding sites have cell- and 
tissue-specific roles in the human host (6, 7), the C-terminal 
domains, 19–20, contain both C3b and polyanion binding sites 
and are key for FH interactions with erythrocytes (8, 9), platelets 
(10–13), endothelial cells (13–15) and neutrophils (16), among 
other ligands.
Mutations in domains 19 and 20 that impair their ability to 
bind to C3b and polyanions are associated with atypical hemo-
lytic uremic syndrome (aHUS) (9, 17, 18), a disease characterized 
by renal failure, hemolytic anemia, and thrombocytopenia (19). 
Thrombocytopenia is a result of excessive platelet activation lead-
ing to increased thrombi formation. While platelet–platelet and 
platelet–endothelium interactions are key for thrombi formation, 
activated platelets can also bind granulocytes to form platelet/
granulocyte aggregates (PGAs). Increased PGA levels enhance 
thromboinflammation in animal models of vascular disease and 
are found in patients suffering from a variety of inflammatory 
vascular conditions, including acute coronary syndromes, inflam-
matory bowel and lung disease, and diabetes (20–22), however, 
it is not known whether increased PGA formation contributes to 
aHUS pathophysiology.
Complement activity enhances PGA formation in human 
whole blood stimulated with thrombin receptor-activating pep-
tide (TRAP) (23–25). Our laboratory has previously shown that 
the AP is key to the effects of complement on PGA formation and 
that a competitive inhibitor of FH C-terminal domains 19 and 20 
(rH19–20), significantly increases AP activity and enhances PGA 
formation in TRAP-stimulated human whole blood (25). By lim-
iting critical FH cell-surface interactions and maintaining fluid-
phase AP regulation, rH19–20 simulates the pathophysiological 
mechanisms involved in aHUS (8), suggesting that increased 
PGA formation could enhance vascular pathology in patients 
suffering from the disease. Here, we sought to better characterize 
the interaction of FH at the platelet/granulocyte interface and to 
determine the effects that mutations in domains 19 and 20 have 
on control of PGA formation in human whole blood.
MaTerials anD MeThODs
Buffers
Modified HEPES/Tyrode’s (HT) buffer (137 mM NaCl, 2.8 mM 
KCl, 1 mM MgCl2 6H2O, 12 mM NaHCO3, 0.4 mM Na2HPO4, 
10  mM HEPES, 0.35% BSA, 5.5  mM glucose; pH 7.4); PBS 
(10  mM NaH2PO4, 140  mM NaCl, pH 7.4); Tyrode’s buffer 
[136.9 mM NaCl, 2.7 mM KCl, 983.8 µM MgCl2 6H2O, 3.2 mM 
Na2HPO4, 3.5 mM HEPES, 0.35% BSA, 5.5 mM dextrose, 2 mM 
CaCl2 (pH 7.4)]; Tyrode’s +  EDTA (Tyrode’s buffer +  10  mM 
EDTA); Tyrode’s + heparin + PGE1 (Tyrode’s buffer + 1 µM PGE1 
and 2 IU/ml heparin); and MgEGTA [0.1 M MgCl2 and 0.1 M 
EGTA (pH7.3)].
Detection antibodies
Murine monoclonal antibodies (all IgG1κ): antihuman CD42b-
APC (BioLegend), antihuman CD45-PE (BioLegend), antihu-
man/mouse C3/C3b/iC3b-FITC and unlabeled (Cedarlane), 
antihuman CD11b-PerCP/Cy5.5 and -PE (BioLegend), antihu-
man CD62P-PE/Cy5 (BioLegend), and goat antimouse-AF488. 
Isotype controls: APC- and PerCP/Cy5.5-labeled (BioLegend), 
PE-labeled (BioLegend), and FITC-labeled (Cedarlane).
serum sources
Properdin-depleted serum and C8-depleted serum were pur-
chased from Complement Technologies.
Production of recombinant Fh Fragments
RH19–20 was produced as previously described (8). Additional 
coding sequence for residues rH1–3, rH2–4, rH3–5, rH6–8, rH7–
9, rH8–10, rH10–12, rH12–14, rH12–15, rH13–15, rH14–16, 
rH15–17, rH16–18, and rH17–19 were PCR amplified (Table 1) 
from a full-length FH cDNA template (26), accession number 
NM_000186. The SapI-digested PCR products were cloned into 
pPICZ-α vector (Invitrogen) containing a His-6 tag and modi-
fied to include SapI sites in its multiple cloning site, as previously 
described (27, 28). Following transformation into Pichia pastoris 
strain KM71H, protein expression was induced with methanol 
following manufacturer’s instructions, deglycosylated by incuba-
tion with endoglycosidase H (New England Biolabs, Ipswich, 
MA, USA), and the proteins were purified from the media by 
affinity chromatography using Ni-NTA Agarose (Qiagen).
RH19–20 mutants were produced as previously described (9). 
Two additional mutants, W1183L and R1215Q, were produced 
as described in the cited reference (9). Concentrations for all 
proteins were determined (280 nm), in triplicate, using theoreti-
cal E cm1
1%  values (e.g., 1.49 for W1183L and W1183R and 1.85 for 
the rest of the mutants) using the Expert Protein Analysis System 
(EXPASY; http://www.expasy.org/tools/protparam.html).
complement inhibitors
Cp20 (Ac-I[CV-1MeW-QDW-Sar-AHRC]mI-NH2), a potent 
compstatin analog, was used to inhibit convertase-mediated 
C3 activation, and was produced by solid phase synthesis (29). 
PMX53 (30) was produced as described. SALO (31) was a gener-
ous donation from Dr. Jesus Valenzuela (National Institutes of 
TaBle 1 | Primers used to amplify coding sequences of several fragments of 
Factor H.
Domains Forward primer 5′ → 3  
(aTaTgcTcTTcaTgc…)
reverse primer 5′ → 3  
(TaTagcTcTTcaaca…)
SCR 1–3 AATGAACTTCCTC 
CAAGAAGAAA
CTTTGGTTTCTCT 
TTACTCCAAAAAC
SCR 2–4 GGACATCCTGG 
AGATACTCC
TGAAGGCAACGG 
ACGCCATC
SCR 3–5 TTACCAGTGACA 
GCACCAGA
TCTCGGAGCAGG 
TATCCAGC
SCR 6–8 GATTATCCAGACA 
TTAAACATGGA
CGTGGGTTGAG 
CTGACCATC
SCR 7–9 TATTTTCCTTATTTG 
GAAAATGGATATAA
TATGGGTAAATCA 
GACCAACCA
SCR 8–10 TCCAAATCAAGTA 
TAGATATTGAG
TATTGGGAGGT 
CAGGAGACA
SCR 10–12 GAACTTCCTAAAAT 
AGATGTACACT
CTGGGGAAGT 
TGGGTCCAT
SCR 12–14 GGAGATATACCTGAA 
CTTGAACAT
GAGTGGTATTGA 
CTGCCATCT
SCR 12–15 GGAGATATACCT 
GAACTTGAACAT
CTGAGGTGGAGA 
ACTCCATTTTC
SCR 13–15 GGAGATATACCTGA 
ACTTGAACAT
CTGAGGTGGAGA 
ACTCCATTTTC
SCR 14–16 CCACCTCCACC 
TCAGATTC
TGATGGAGGGTG 
AGACCATTT
SCR 15–17 TCACAACCACCT 
CAGATAGAAC
TGTTGGCCTTCC 
TGTCCATC
SCR 16–18 AAATCTCCACCTG 
AGATTTCTCAT
TTGAGGTGGTTCCGTCCAG
SCR 17–19 CTCAGTTTACCTAGC 
TTTGAAAATG
TTTTGGTGGTTCT 
GACCATTGTC
Underlined are the nucleotide sequences containing the SAPI restriction site that are 
added in each primer.
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Health). Eculizumab was purchased from Creative Biolabs, 
and OmCI (32) was a generous donation from Dr. Susan Lea 
(University of Oxford). Human IgG4 isotype control (BioLegend) 
was used as a control for Eculizumab.
Purification of Properdin and separation 
of Physiological Properdin Forms
Properdin was isolated from human plasma, as previously 
described (33). For some experiments, properdin dimers, 
trimers, and tetramers (P2, P3, and P4) were separated from 
non-physiological aggregates (Pn), stored at 4°C, and used within 
2 weeks of separation, as previously described (33, 34).
Ex Vivo Whole Blood assay for Detecting 
Pga Formation
Human whole blood was obtained via venipuncture from volun-
teer donors. The Institutional Review Board from the University 
of Toledo College of Medicine and Life Sciences approved the 
protocols, and written informed consent was obtained from all 
donors, in accordance with the Declaration of Helsinki. Blood 
was drawn into vacutainer tubes (Becton Dickinson) containing 
50 µg/ml final concentration of the thrombin inhibitor lepirudin 
(Celgene). 20 µl of whole blood was gently mixed with modified 
HT buffer + 10 µM TRAP (Bachem) and complement modulators, 
for a final volume of 80 µl. All groups were set up in duplicate. 
Samples were incubated at 37°C for 15 min and the reaction was 
stopped by addition of 800  µl RBC lysation/fixation solution 
(BioLegend). Samples were fixed for 10 min at room temperature 
(RT) before being washed, stained with detection antibodies for 
15  min at RT, then diluted with 800  µl RBC fixation/lysation 
solution. Finally, samples were spun at 200 g for 15 min at 4°C, 
then 500 µl supernatant was removed and the samples run on a 
FACSCalibur (Becton Dickinson) flow cytometer. 10,000 events 
were acquired from a gate encompassing granulocyte and mono-
cyte populations. Using FlowJo software version 7.6 (Tree Star), 
granulocytes were gated based on CD45 and side scatter, and the 
percent of granulocytes positive for CD42b fluorescence, as well 
as the C3- and CD11b-associated geometric mean fluorescent 
intensities (GMFIs) on gated granulocytes, were determined.
Detection of c5a
Whole blood assays were set up as described, but in triplicate. 
Following the 37°C incubation, one replicate was immediately 
placed on ice then spun at 300 g for 10 min at 4°C. The other 
two replicates were processed via flow cytometry, as described 
above. Supernatants were spun at 13,000 g for 5 min at 4°C, then 
immediately frozen at −80°C until use. Supernatants were diluted 
1/10 and C5a levels determined via standard ELISA kit (Abcam) 
following manufacturer’s instructions.
Platelet isolation and activation
Platelets were isolated from human whole blood as previously 
described (12). Briefly, blood from volunteer donors was drawn 
into acid citrate dextrose vacutainers via venipuncture then spun 
at 200 g for 15 min at RT without braking. Platelets were washed 
twice with acid citrate wash buffer at 440  g for 10  min at RT, 
then resuspended in Tyrode’s buffer. Platelets (1 × 108/ml) were 
activated with thrombin (1  U/ml) for 30  min at 37°C and the 
reaction stopped by the addition of Tyrode’s + heparin + PGE1, 
as previously described (12).
isolation of neutrophils
Neutrophils were isolated from EDTA-anticoagulated human 
whole blood via Polymorphprep gradient centrifugation, using 
the manufacturer’s protocol (12). Briefly, whole blood was layered 
over Polymorphprep in a 1:1 ratio, then spun at 500 g for 35 min 
(without brake) at RT. The neutrophil layer was obtained from the 
gradient and washed with an equal volume of half-strength HBSS, 
without Ca+2 or Mg+2 (Life Technologies), at 400 g for 10 min at 
RT. Contaminating erythrocytes were lysed by a 7-min incuba-
tion in RBC lysis buffer (BioLegend) at 37°C, pelleted at 400 g 
for 10 min at RT, then finally resuspended in HBSS + 0.2% BSA.
Measurement of aP activation on 
Platelets
For mapping experiments, non-activated or thrombin-activated 
platelets were preincubated with 25 µg/ml properdin oligomers 
(P2–P4) in a 1:2:1 ratio for 1 h at RT, as previously described (12). 
Platelets (2 × 107/ml) were washed, then incubated with 18 µM rH 
fragments, 5 mM MgEGTA, and 60% properdin-depleted serum 
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for 30 min at 37°C in a total reaction volume of 100 µl. The reac-
tion was stopped by washing samples with cold Tyrode’s + EDTA. 
C3 fragment deposition on the platelet surface was assessed by 
incubation with unlabeled anti-C3/C3b/iC3b for 60 min at 4°C, 
followed by AF488-goat-antimouse for 45 min at 4°C. Platelets 
were then stained with anti-CD42b and anti-CD62P for 45 min 
at 4°C, before being fixed with 1% paraformaldehyde for 30 min 
at 4°C. Platelets were gated via FSC and CD42b-fluorescence and 
at least 10,000 events were acquired.
For rH19–20 mutant studies, the experimental set-up was 
identical with the following exceptions: (1) platelets were 
incubated with 1  µg/ml unfractionated properdin rather than 
properdin oligomers to induce complement activation on the 
thrombin-activated platelet surface. 1  µg/ml of unfractionated 
properdin activates complement to the same extent as 25 µg/ml 
P2–P4 on platelets (not shown) due to the presence of aggregated 
properdin in unfractionated preparations (12, 33); (2) thrombin-
activated platelets were used at 1 × 107/ml during the incubation 
with properdin-depleted serum; (3) thrombin-activated platelets 
incubated in the presence of wild-type (WT) rH19–20 and Cp20 
were used as the negative control in lieu of non-activated plate-
lets; and (4) C3 fragment deposition was assessed using a FITC-
labeled anti-C3/C3b/iC3b monoclonal antibody, simultaneously 
with the anti-CD42b and anti-CD62P incubation.
Measurement of aP activation on 
neutrophils
For both mapping and rH19–20 mutant studies, isolated neu-
trophils (2 ×  106/ml) were mixed with HBSS +  0.2% BSA, rH 
constructs and other complement modulators (Cp20 and FH) in 
the presence of C8-depleted serum (33%) and 2.5 mM MgEGTA 
or 10 mM EDTA (negative control) for 5 min at 37°C. Final con-
centrations of rH constructs and other reagents are indicated in 
figure legends. Reactions were stopped with the addition of cold 
HBSS + 0.2% BSA containing 10 mM EDTA. Cells were washed 
then stained with anti-C3/C3b/iC3b-FITC and anti-CD11b-
PE for 15  min at 4°C before being run on the flow cytometer. 
Neutrophils were gated via SSC and CD11b-fluorescence and 
propidium iodide was used for live/dead cell discrimination. 
At least 5,000 events (live neutrophils) were acquired, and the 
C3-associated GMFI on live neutrophils was determined.
statistics
GraphPad Prism 6.0 was used to analyze data. One-way ANOVA 
with multiple comparison tests (indicated in figure legends) 
was used to determine statistical significance between groups. p 
values less than 0.05 were considered statistically significant.
resUlTs
Domains 19 and 20 are Most critical for 
Fh regulation on cells involved in Pga 
Formation
Platelets (12) and neutrophils (35) both activate the AP on 
their surface. Isolated platelets and neutrophils, in the absence 
of serum, bind FH primarily via its C-terminus (10, 11, 16). 
FH binds to multiple ligands (gpIIb/IIIa and tsp-1) on isolated 
platelets (10, 36), however, it is unknown what regions contribute 
to FH function when the AP is activating. Although Saggu et al. 
(12) determined that the C-terminus of FH is important for its 
interaction with platelets during complement activation, no one 
has systematically tested whether other domains of FH contribute 
to binding and protecting the platelet surface. Also, it remains 
unknown how FH interacts with neutrophils to protect them in 
the presence of serum. Therefore, we mapped FH protection from 
complement on the surface of isolated platelets and neutrophils to 
determine the regions most critical for FH cell surface protection 
on cells involved in PGA formation.
Recombinant fragments of FH (rH), spanning the length of 
the protein, were mixed with each cell type and serum under con-
ditions that would specifically activate the AP. Fragments that can 
compete with FH for binding to the cell surface displace FH from 
the cell surface, leading to an increase in C3 fragments deposited 
on the cell. On both thrombin-activated platelets (Figure  1A) 
and neutrophils (Figure 1B), only rH19–20, composed solely of 
C-terminal domains 19–20, led to an increase in C3 fragments 
detected on the cell surface. RH19–20 increased C3 fragment 
deposition on platelets (Figure 1A) and neutrophils (Figure 1B) 
by ~3–4-fold and ~1.5–2-fold over cells incubated without rH 
fragments, respectively. Cumulatively, the data indicate the 
C-terminus is the most critical region of FH for protecting both 
isolated platelets and neutrophils from the AP. Moreover, the 
results indicate that rH19–20 can be used as an effective competi-
tive inhibitor of FH function on these cell surfaces.
effects of Fh on neutrophils are 
complement-Dependent
Because FH has been reported to enhance neutrophil degranu-
lation/activation by binding to complement receptor 3 (CR3; 
CD11b/CD18; Mac-1) (16, 37, 38), we determined whether 
rH19–20 or FH had any complement-independent functions in 
our in vitro neutrophil experiments. Cp20, a potent compstatin 
analog that inhibits all convertase-mediated complement activa-
tion (29), completely abrogated C3 fragment deposition in the 
absence or presence of rH19–20 (Figure  2). Furthermore, the 
addition of ~200 μg/ml FH reduced C3 fragment deposition to 
approximately the same level as the EDTA control and did not 
enhance C3 fragment deposition on neutrophils in the presence 
of Cp20. This indicates that in our experimental set-up, the 
effect of rH19–20 (and exogenous FH) is restricted to its ability 
to dysregulate AP activity through inhibition of FH cell surface 
interactions.
Domains 19–20 are Most critical for 
limiting TraP-Mediated Pga Formation
We previously demonstrated domains 19–20 were critical for FH 
regulation on granulocytes in TRAP-stimulated whole blood (25), 
however, it is unknown whether other regions of FH help anchor 
the protein to the granulocyte surface. FH contains C3b and poly-
anion binding domains in its central region, however, the location 
and number of these binding domains remains controversial 
(5, 26, 39, 40). We used our whole blood PGA assay to achieve 
FigUre 2 | Effects of rH19–20 on C3 fragment deposition on neutrophils are 
complement-dependent. Neutrophils (2 × 106/ml) were incubated without or 
with rH19–20 (20 µM) or Factor H (FH) (1.3 µM) ± Cp20 (50 µM) and 33% 
C8-depleted serum in the presence of 2.5 mM MgEGTA. Samples that 
received 10 mM EDTA were included as negative controls. C3 fragment 
deposition on neutrophils was determined as described in Section “Materials 
and Methods.” Results are representative of two independent experiments 
done with neutrophils from different human volunteer donors and are 
graphed as mean and SD of duplicate observations. The data were analyzed 
by one-way ANOVA with Tukey’s multiple comparison test. p < 0.001 (***).
FigUre 1 | Factor H (FH) C-terminal domains are most critical for control of 
the alternative pathway on platelets and neutrophils. (a) Thrombin-activated 
platelets preincubated with 25 µg/ml P2–P4 (Thr + P; 2 × 107/ml) were 
incubated without or with rH fragments (18 µM) in the presence of 5 mM 
MgEGTA and 60% properdin-depleted serum. Assuming 3 µM FH in serum, 
the molar ratio of rH:FH was ~10:1. Non-activated (NA) platelets were 
included as negative controls. C3 fragment deposition on platelets was 
determined as described in Section “Materials and Methods.” Results are 
representative of independent experiments done with platelets from different 
human volunteer donors that tested the entire rH fragment panel and are 
graphed as mean and SD of triplicate observations, n = 2. The data were 
analyzed by one-way ANOVA with Dunnett’s multiple comparison test against 
Thr + P. p < 0.001 (***). (B) Neutrophils (2 × 106/ml) were incubated without 
or with rH fragments (20 µM) and 33% C8-depleted serum in the presence of 
2.5 mM MgEGTA. Assuming 3 µM FH in serum, the molar ratio of rH:FH was 
~20:1. Samples that received 10 mM EDTA were included as negative 
controls. C3 fragment deposition on neutrophils was determined as 
described in Section “Materials and Methods.” Results are representative of 
independent experiments done with neutrophils from different human 
volunteer donors that tested the entire rH fragment panel (indicated in each 
graph) and are graphed as mean and SD of duplicate observations, n = 2. 
The data were analyzed by one-way ANOVA with Dunnett’s multiple 
comparison test against MgEGTA alone. p < 0.05 (*) and p < 0.001 (***).
5
Blatt et al. Factor H Regulates PGA Formation
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1586
very high competitive molar ratios of recombinant fragments to 
FH (~44:1, rH:FH), in order to detect potential weak effects of 
domains in the contested region of FH. Three fragments other 
than rH19–20 led to significant increases in TRAP-mediated 
PGA formation in at least three of seven experiments: rH8–10, 
rH12–15, and rH14–16. Figure 3A is representative of an experi-
ment in which all three of these fragments significantly increased 
TRAP-mediated PGA formation. In all seven experiments, 
rH19–20 significantly increased PGA formation relative to TRAP 
alone and the increase in PGA formation was always greater than 
for any other fragment (Figure 3A), indicating the C-terminus 
is the most critical region of FH for regulating PGA formation 
in TRAP-stimulated human whole blood. Moreover, rH19–20 
was the only fragment that increased C3 fragment deposition 
on granulocytes relative to TRAP alone (Figure  3B), which is 
consistent with its critical role in mediating regulation of the AP 
on both platelets and neutrophils (Figure 1). No other fragment 
had a statistically significant effect on C3 fragment deposition in 
any of seven experiments (Figure  3B). Because C5a is the key 
complement effector molecule for PGA formation (23–25), C5a 
levels correlate with PGA formation (25), and C5a detection 
is more sensitive in our hands than detection of C3 fragment 
deposition, we measured C5a levels in PGA reaction superna-
tants in the presence of fragments containing domains spanning 
from 6 to 17 as a more sensitive way to determine whether the 
effects of the fragments on PGA formation were complement-
dependent. RH19–20 led to the greatest increase in C5a levels, 
up to an ~7-fold increase over TRAP alone (Figure 3C). Of the 
three other fragments that led to increases in PGA formation, 
only rH8–10 led to significant increases in C5a generation in all 
three experiments, although the fold-increase in C5a over TRAP 
alone was significantly lower than for rH19–20 alone (~1.5-fold) 
(Figure  3C). Collectively, the results suggest that of the three 
fragments of interest (rH8–10, rH12–15, and rH14–16), rH8–10 
is actually competing with FH, while the effects of the other 
fragments require further study to determine the real biological 
significance of their contribution and may depend on the level of 
circulating FH in each donor’s blood. Fragments rH6–8, rH7–9, 
rH12–14, rH13–15, and rH15–17, which also contain domains 
previously described to have weak C3b and/or polyanion bind-
ing regions (5, 26, 39, 40) had no effect on PGA formation, C3 
FigUre 3 | Domains 19–20 are critical for regulation of platelet/granulocyte aggregate (PGA) formation and alternative pathway activity in thrombin receptor-
activating peptide (TRAP)-stimulated whole blood. 20 µl of lepirudin anticoagulated whole blood was incubated with TRAP (10 µM) ± rH fragments (20 µM), in a total 
80 µl volume. Assuming 3 µM Factor H (FH) in each donors’ plasma and 60% plasma per blood sample, the molar ratio of rH:FH was ~44:1. Samples that did not 
receive TRAP [non-activated (NA)] and that were preincubated with Cp20 (NA + Cp20) were included in (a–c). (a) PGA formation, (B) C3 fragment deposition, and 
(c) C5a generation were determined as described in Section “Materials and Methods.” (a) Graph is representative of at least three independent experiments (out of 
seven) in which rH8–10, rH12–15, and rH14–16 showed significant increases in PGA formation. (B) Graph is representative of seven independent experiments in 
which only rH19–20 showed significant increases in C3 fragment deposition in all seven experiments. (c) Graph is representative of three independent experiments 
in which rH8–10 and rH19–20 showed significant increases in C5a generation in all three experiments. The data were analyzed by one-way ANOVA with Dunnett’s 
multiple comparison test against TRAP alone. p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
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fragment deposition, or C5a generation relative to TRAP alone 
(Figures 3A–C), reducing the possibility of non-specific effects of 
rH8–10, rH12–15, and rH14–16 due to their polyhistidine tags. 
Cumulatively, these data indicate the C-terminus is the most 
important region for targeting FH to the platelet/granulocyte 
interface, although weak interactions with domains between 8 
and 16 may enhance FH cell-surface protection.
c5a is the Key complement effector 
Molecule for Pga Formation When Fh cell 
surface Protection is Dysregulated
C5a is the key complement effector molecule influencing TRAP-
mediated PGA formation under normal regulation (23–25). 
Additional complement-mediated mechanisms involved in the 
interaction between platelets and granulocytes include the ability 
of neutrophils to bind platelets through a CR3-C3(H2O) interac-
tion (24), and enhanced platelet activation by MAC (41–43), both 
of which could account for some of the effect of complement on 
PGA formation. Because decreased FH cell surface protection 
increases the generation of all complement effector molecules, 
we sought to determine whether C5a remained the key comple-
ment effector molecule for enhancing PGA formation in the 
presence of rH19–20. Therefore, we tested the ability of PMX53, 
a C5a receptor 1 (C5aR1) antagonist previously shown to inhibit 
properdin-mediated increases in PGA formation (25), to inhibit 
rH19–20-mediated increases in PGA formation. Eculizumab 
and OmCI, two reagents that prevent C5 cleavage, were included 
FigUre 4 | C5a is the key effector molecule for platelet/granulocyte aggregate (PGA) formation in the presence of dysregulated Factor H (FH) cell surface 
protection. 20 µl of lepirudin anticoagulated whole blood was incubated with thrombin receptor-activating peptide (TRAP) (10 µM) without or with rH19–20 
(10 µM) ± anticomplement reagents (Cp20: 50 µM, PMX53: 16.7 µM, OmCI: 0.5 µM, and Eculizumab and IgG4 isotype control: 100 µg/ml), in a total 80 µl volume. 
Assuming 3 µM FH in each donors’ plasma and 60% plasma per blood sample, the molar ratio of rH:FH was ~22:1. A sample that did not receive TRAP [non-
activated (NA)] or that was preincubated with Cp20 (NA + Cp20) was included for A and B, respectively. (a) PGA formation and (B) C5a generation were 
determined as described in Section “Materials and Methods.” Graphs are representative of (a) three and (B) two independent experiments done with blood from 
different human volunteer donors. Results are shown as mean and SD of duplicate observations. The data were analyzed by one-way ANOVA with Tukey’s multiple 
comparison test. p < 0.001 (***) and p > 0.05 (n.s.).
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to determine whether there were potential differences between 
inhibition of only C5a function (with PMX53) versus inhibition 
of both C5a and MAC formation. Eculizumab is a humanized 
recombinant IgG2/IgG4 anti-C5 monoclonal antibody, and 
OmCI is a tick salivary protein (32). Cp20 was included as 
a positive control for complete complement inhibition, and 
an IgG4 isotype control antibody was used as a control for 
Eculizumab. PMX53, Eculizumab, and OmCI, but not the IgG4 
isotype control, completely abrogated the effects of rH19–20 on 
PGA formation, decreasing PGA formation to the level seen in 
samples receiving Cp20 (Figure 4A). The inhibitory reagents also 
completely abrogated rH19–20-mediated increases in C5a gen-
eration, with PMX53 being the only exception, as expected, since 
it inhibits C5a function rather than its generation (Figure 4B). 
The data indicate that C5a-C5aR1 interactions play a critical role 
in enhancing PGA formation in the presence of dysregulated FH 
cell surface protection.
effects of rh19–20 are Primarily Mediated 
by spontaneous aP activity
We previously showed that the effects of rH19–20 on PGA forma-
tion are completely abrogated by inhibition of properdin function 
or all AP activity (25). FH regulates AP activity, however, the 
AP can activate spontaneously or amplify complement activity 
initiated by the classical or lectin pathways. The classical pathway 
plays an important role in initiating complement activity when 
FH regulation is intact (25). To determine whether the classical 
pathway also plays a role in PGA formation when FH cell-
surface protection is dysregulated, we tested the ability of SALO, 
a specific classical pathway inhibitor (31) at 2  µM (10–20-fold 
above the reported IC50), to limit rH19–20-mediated effects on 
PGA formation. Cp20 and PMX53 were included as controls for 
complete inhibition of PGA formation. Through 3 independent 
experiments, SALO inhibited the effects of rH19–20 on PGA 
formation by ~50%, whereas Cp20 and PMX53 completely 
abrogated the effects of rH19–20 (Figure 5A). These results were 
in agreement with the pattern of effects on C5a levels in reaction 
supernatants (Figure 5B). Our results combined with previous 
data (25) suggest that in the absence of FH cell surface protection, 
the effects of complement on PGA formation are primarily medi-
ated by spontaneous AP activation, with a partial contribution 
from the classical pathway.
ahUs-related Mutations have Differential 
effects on control of Pga Formation and 
complement activity in TraP-stimulated 
Whole Blood
Atypical hemolytic uremic syndrome is a prothrombotic disease 
associated with mutations mainly in FH domains 19–20 (19). The 
addition of rH19–20 to whole blood simulates pathophysiologic 
mechanisms involved in aHUS by competitively impairing FH 
cell surface protection, without affecting fluid phase regulation 
(8). Since rH19–20 leads to increases in TRAP-mediated PGA 
formation, this suggests that increased PGA formation may 
contribute to the thrombosis seen in patients with aHUS, there-
fore, we next assessed the effects of aHUS-related mutations in 
domains 19–20 on FH control of PGA formation. We utilized 14 
rH19–20 constructs containing mutations that alter the affinity 
of the constructs for C3b and/or heparin (9). Ten mutations are 
FigUre 5 | Effects of rH19–20 on platelet/granulocyte aggregate (PGA) formation are primarily mediated by C5a that is not generated by CP activity. 20 µl of 
lepirudin anticoagulated whole blood was incubated with thrombin receptor-activating peptide (TRAP) (10 µM) without or with rH19–20 (10 µM) ± anticomplement 
reagents (SALO: 2 µM, Cp20: 50 µM, PMX53: 16.7 µM), in a total 80 µl volume. Assuming 3 µM FH in each donors’ plasma and 60% plasma per blood sample, the 
molar ratio of rH:FH was ~22:1. A sample that did not receive TRAP [non-activated (NA)] or that was preincubated with Cp20 (NA + Cp20) was included for A and 
B, respectively. (a) PGA formation and (B) C5a generation were determined as described in Section “Materials and Methods.” Graphs are representative of three 
independent experiments done with blood from different human volunteer donors. Results are shown as mean and SD of duplicate observations. The data were 
analyzed by one-way ANOVA with Tukey’s multiple comparison test. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p > 0.05 (n.s.).
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associated with aHUS in humans (44), whereas the remaining 4 
mutations (K1188Q, R1203S, R1210S, and K1230A) were previ-
ously designed to investigate the C3b and polyanion-binding 
sites of the FH C-terminus (9) and have not been associated with 
disease. When added to TRAP-stimulated whole blood, the aver-
age effects of the mutants on PGA formation (Figure  6A), C3 
fragment deposition (Figure 6B), C5a generation (Figure 6C), 
and CD11b expression (Figure 6D) varied. The average level of 
PGA formation was higher (albeit with varying significance) in 
the presence of all mutants except D1119G and R1215Q com-
pared to the average level of PGA formation seen with TRAP 
alone (Figure  6A). This indicates that the majority of mutants 
can at least partially compete with FH and induce PGA formation 
despite having altered affinities for C3b and heparin (when meas-
ured individually) (9). Five mutants (W1183L, T1184R, R1203S, 
R1210S, and K1230A) significantly increased C3 fragment 
deposition compared to TRAP alone (Figure 6B). Four of these 5 
mutants (all but W1183L), led to average C3 fragment levels equal 
to or greater than the average level seen with WT (assigned a 
value of 1). The same five mutants that led to significant increases 
in C3 fragment deposition also significantly increased C5a levels 
compared to TRAP alone (Figure 6C). The average level of C5a 
in the supernatants of samples receiving these five mutants were 
greater than or equal to the average level seen with WT (assigned 
a value of 1).
The average effects of the other mutants on C3 fragment 
deposition and C5a generation were more variable, with many 
failing to increase either parameter over the average level 
observed with TRAP alone. Specifically, mutants D1119G, 
R1182S, W1183R, K1188Q, S1191L, S1191L/V1197A, R1215G, 
and R1215Q resulted in no significant increases in average 
levels of C3 fragment deposition and C5a generation versus 
TRAP alone, indicating that these mutants (all aHUS related, 
except the designer mutant K1188Q) are affected in their ability 
to compete with normal FH-mediated protection. The average 
of effects of the mutants on CD11b expression were variable, 
but only T1184R led to significant increases in CD11b expres-
sion compared to TRAP alone (Figure  6D). This reflects the 
inconsistency in the effects of rH19–20 on CD11b expression, 
as observed previously (25). The average effects of the mutants 
on PGA formation did, however, correlate with the average 
effects of the mutants on CD11b expression (Figure  7C), as 
well as C3 fragment deposition (Figure 7A) and C5a genera-
tion (Figure 7B). Collectively, these data indicate that while the 
mutations do not universally impair the ability of the rH19–20 
constructs to compete with FH in TRAP-stimulated whole 
blood, there are some mutations that may lead to enhanced 
PGA formation in patients with aHUS.
Pattern of rh19–20 Mutant impairment on 
Platelets and neutrophils is similar to the 
Pattern seen in Whole Blood
Finally, we aimed to determine whether the mutants were 
preferentially impaired on either the surface of platelets or 
neutrophils. To that end, we examined the effects of 11 of the 
mutants on control of the AP on isolated platelets and neutro-
phils. Five mutants significantly increased C3 fragment deposi-
tion compared to thrombin-activated platelets with properdin 
alone (Figure 8A) and seven mutants significantly increased C3 
fragment deposition compared to neutrophils incubated with 
MgEGTA alone (Figure 8B). T1184R and R1203S significantly 
FigUre 6 | RH19–20 mutants have differential effects on platelet/granulocyte aggregate (PGA) formation and alternative pathway activity in thrombin receptor-
activating peptide (TRAP)-stimulated whole blood. 20 µl of lepirudin anticoagulated whole blood was incubated with TRAP (10 µM) in the absence or presence of 
wild-type (WT) or mutant rH19–20 constructs (10 µM), in a total 80 µl volume. Assuming 3 µM Factor H (FH) in each donors’ plasma and 60% plasma per blood 
sample, the molar ratio of rH:FH was ~22:1. A sample that did not receive TRAP [non-activated (NA)] and that was preincubated with Cp20 (NA + Cp20) was 
included for A and B-D, respectively. (a) PGA formation, (B) C3 fragment deposition, (c) C5a generation, and (D) CD11b expression were determined as described 
in Section “Materials and Methods.” Each graph represents cumulative data from experiments carried out with different human volunteer blood donors (n = 3 for 
each mutant), and is graphed as the mean and SD for each mutant relative to WT (assigned a value of 1) for each independent experiment. Seven total experiments 
were conducted to test each mutant three times, therefore, the NA and TRAP alone groups represents the average value for all seven experiments. Red line: 
reference point for “+WT”; blue line: reference point for TRAP “Alone.” The four designer mutants that are not associated with disease (K1188Q, R1203S, R1210S, 
and K1230A) are grouped to the right of the graph. Data were analyzed by one-way ANOVA with Dunnett’s multiple comparison test against TRAP alone. p < 0.05 
(*), p < 0.01 (**), and p < 0.001 (***).
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increased C3 fragment deposition on both cells to a level that was 
approximately equal to or greater than the average level seen with 
WT (assigned a value of 1; Figures 8A,B), consistent with their 
statistically significant effects on PGA formation and AP activity 
in TRAP-stimulated whole blood (Figures 6A–C). Interestingly, 
W1183R significantly increased C3 fragment deposition on both 
cell types to approximately the same level as WT (Figures 8A,B), 
despite having no statistically significant effects on C3 fragment 
deposition or C5a generation in TRAP-stimulated whole blood 
(Figures 6B,C). L1189F and S1191L also had significant effects 
on C3 fragment deposition on both platelets (Figure  8A) and 
neutrophils (Figure  8B), while W1183L and S1191L/V1197A 
significantly increased C3 fragment deposition on neutrophils 
(Figure  8B). Mutants D1119G, R1182S, R1215G, and R1215Q 
were consistently affected in their ability to increase C3 deposition 
on both cell types, indicating that these aHUS-related mutants 
are impaired in their ability to effectively compete with FH for 
protection of these cell surfaces.
FigUre 7 | Effects of rH19–20 mutants on platelet/granulocyte aggregate (PGA) formation correlate with effects on C3 fragment deposition, C5a generation, and 
CD11b expression. The mean effect of each mutant on PGA formation relative to wild-type (WT) (red; assigned a value of 1) is graphed on the X-axis, and the mean 
effect of each mutant on (a) C3 fragment deposition, (B) C5a generation, and (c) CD11b expression relative to WT is graphed on the Y-axis. Data were analyzed by 
Pearson’s correlation test. The r value is displayed on each panel. p < 0.001 for all panels.
10
Blatt et al. Factor H Regulates PGA Formation
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1586
Overall, the pattern of the effects of the mutants was very simi-
lar to the pattern of their effects on PGA formation. The mutants 
that were least (T1184R, R1203S) or most (D1119G, R1182S, 
R1215G, R1215Q) impaired relative to WT in their effects on PGA 
formation, C3 fragment deposition, C5a generation, and CD11b 
expression (Figure  6), remained the least or most impaired in 
C3 fragment deposition relative to WT on the surface of both 
cell types (Figure 8). The average effects of the mutants on PGA 
formation and C3 fragment deposition in the whole blood PGA 
assay correlated with average effects of the mutants on C3 fragment 
deposition on isolated platelets (Figures 9A,C) and neutrophils 
(Figures 9B,D). There was not a significant correlation between 
the average effects of the mutants on C3 fragment deposition on 
isolated platelets and neutrophils (Figure  9E), suggesting that 
the mutants may recognize slightly different ligands on each 
cell surface. Altogether, results from Figures  6–9 indicate that 
aHUS-related mutations have differential effects on FH-mediated 
control of the AP on platelets and on neutrophils, which reflect 
their ability to control PGA formation. Therefore, FH is key 
for regulating PGA formation and AP activity on platelets and 
neutrophils and some aHUS-related mutations, including but not 
limited to D1119G, R1182S, R1215G, and R1215Q, may lead to 
an increased propensity to form PGAs that increase thrombosis 
in patients with the disease.
DiscUssiOn
Atypical hemolytic uremic syndrome is a debilitating disease 
characterized by a triad of symptoms, including renal failure, 
hemolytic anemia, and excessive thrombosis leading to throm-
bocytopenia (19). Impaired FH cell surface protection is not only 
associated with aHUS, but also with increased PGA formation 
(25), a phenomenon that can cause pathologic thromboinflam-
mation when in excess (20–22). Despite associations between 
decreased FH cell surface protection and aHUS, as well as 
increased PGA formation, it is unknown whether patients suf-
fering from aHUS have increased levels of circulating PGAs in 
their blood. Here, we have elaborated on previous work that 
elucidated a key role for FH in controlling PGA formation (25), 
establishing the C-terminus as the most critical region of FH for 
controlling AP activity under thromboinflammatory conditions 
and identifying differential effects of aHUS-related mutations 
FigUre 8 | rH19–20 mutants have differential effects on control of the alternative pathway on platelets and neutrophils. (a) Thrombin-activated platelets 
preincubated with 1 µg/ml unfractionated properdin (Thr + P; 1 × 107/ml) were incubated without or with wild-type (WT) or mutant rH19–20 constructs (25 µM) in 
60% properdin-depleted serum in the presence of 5 mM MgEGTA. Assuming 3 µM Factor H (FH) in serum, the molar ratio of rH:FH was ~14:1. A sample that 
received Cp20 (50 µM) was also included. (B) Neutrophils (2 × 106/ml) were incubated without or with WT or mutant rH19–20 constructs (20 µM) in 33% 
C8-depleted serum in the presence of 2.5 mM MgEGTA. Assuming 3 µM FH in serum, the molar ratio of rH:FH was ~20:1. A sample that received 10 mM EDTA 
was also included. C3 fragment deposition on (a) platelets and (B) neutrophils was determined as described in Section “Materials and Methods.” Each graph 
represents cumulative data from experiments carried out with different human volunteer blood donors (n = 2 for each mutant), and is graphed as the mean and SD 
for each mutant relative to WT (assigned a value of 1) for each independent experiment. Four total experiments were needed to test each mutant twice, therefore, 
the EDTA and MgEGTA alone groups represent the average for all four experiments. Red line: reference point for “+WT”; blue line: reference point for TRAP “Alone.” 
R1203S is a designer mutant not associated with disease. Data were analyzed by one-way ANOVA with Dunnett’s multiple comparison test against (a) Thr + P or 
(B) MgEGTA alone. p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
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on PGA formation. Our data expand the current perception 
of regulatory mechanisms controlling PGA formation and has 
important implications for understanding the pathophysiologic 
mechanisms involved in aHUS.
In vitro mapping studies demonstrated that FH C-terminal 
domains are the most critical part of the protein for anchoring 
FH to activated platelets and neutrophils in order to limit C3 
fragment deposition (Figures 1A,B). Our results were in agree-
ment with previous mapping studies that also showed domains 
19–20 were critical for binding to platelet and neutrophil surfaces 
(10, 11, 16). These reports, however, utilized isolated cells in the 
absence of a source of active complement and identified integrin 
receptors (GPIIb/IIIa; CR3) as key FH ligands. The surfaces of 
both activated platelets and neutrophils serve as a platform for 
the activation of the AP (12, 35), thus these studies neglected the 
role of C3b (a primary ligand for FH) deposited on cells under 
thromboinflammatory conditions in which the AP is activating. 
We confirmed a critical role of the C-terminus of FH in allowing 
FH to carry out its regulatory functions on the cell surface during 
complement activation (Figures 1 and 2). While domain 7 was 
shown to bind to both isolated platelets and neutrophils (10, 16), 
we detected no role for this domain on either cell type in the 
presence of active complement (Figure 1), suggesting that dual 
recognition of C3b and polyanions by the C-terminus is more 
critical than domain 7-mediated polyanion binding alone under 
the conditions used in this study. We did not use, however, a 
fragment containing domain 7 at the C-terminus as is present in 
FHL-1, a naturally truncated form of FH composed of domains 
1–7 (2). C-terminal positioning of domain 7 may be relevant for 
effective interactions with the cell surface, thus we cannot exclude 
the possibility that FHL-1 may have a role in regulating PGA 
formation.
RH19–20 also had the most potent effects on PGA formation, 
C3 fragment deposition, and C5a generation in our ex vivo whole 
blood assay (Figure 3). Higher theoretical rH:FH ratios (~44:1, 
assuming a concentration of 3  µM FH in each donors’ plasma 
and 60% plasma per blood sample) in the whole blood assay 
allowed detection of weak but significant effects of fragments 
rH8–10, 12–15, and 14–16 on PGA formation in about half of our 
experiments, however, no effects were observed on C3 fragment 
deposition (Figures 3A,B). Furthermore, only rH8–10 consist-
ently had effects on C5a generation (Figure 3C). Pangburn et al. 
previously identified a polyanion binding site within domains 
11–15 (39) and demonstrated the importance of this region in 
limiting complement on self but not activating surfaces (6), thus 
the reasons for the lack of a clear complement-dependent effect 
on PGA formation by rH12–15 and rH14–16 remain a conun-
drum. The lack of effects on PGA formation by other fragments 
containing domains between 12 and 16 (e.g., rH12–14, rH13–15) 
likely rules out non-specific effects of rH12–15 and rH14–16 due 
to polyhistidine tags. RH12–15 and rH14–16 may contain unique 
binding sites due to the biochemical and structural properties 
FigUre 9 | Correlation of the effects of mutants on platelet/granulocyte aggregate (PGA) formation and alternative pathway activity in thrombin receptor-activating 
peptide (TRAP)-stimulated whole blood with the effects on control of alternative pathway activity on isolated platelets and neutrophils. The mean effect of each 
mutant on (a,c) PGA formation or (B,D) C3 fragment deposition on granulocytes in TRAP-stimulated whole blood relative to wild-type (WT) (red; assigned a value of 
1) is graphed on the X-axis, and the mean effect of each mutant on C3 fragment deposition on isolated (a,B) platelets and (c,D) neutrophils relative to WT is 
graphed on the Y-axis. (e) Graph represents mean effects of mutants on C3 fragment deposition relative to WT on platelets and neutrophils on X and Y axes, 
respectively. Data were analyzed by Pearson’s correlation test. The r value is displayed on each panel. (a–D) p < 0.05 and (e) n.s.
12
Blatt et al. Factor H Regulates PGA Formation
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1586
of their individual domains that are not present on the other 
non-effective fragments. These binding sites may influence PGA 
formation via weak interactions with cell surface polyanions or 
other unknown ligands in TRAP-stimulated whole blood, which 
would need to be determined experimentally. The effects of 
rH8–10 may correspond to the C3b binding capability of domain 
8 (5, 26), although it remains to be determined why rH6–8 would 
not show similar increases. The ability of rH8–10 to increase C5a 
generation without affecting C3 fragment deposition may be due 
to the greater sensitivity of the C5a detection assay in our hands. 
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While further studies of the role of the middle region of FH are 
warranted, the lack of consistent and potent effects of fragments 
outside domains 19–20 on PGA formation and AP activity, despite 
very high competitive ratios of rH fragment to circulating FH in 
our system, indicate domains 19–20 are unequivocally the most 
important for targeting FH to the platelet/granulocyte interface 
and that other regions have a limited role.
Inhibition of C5 cleavage or blocking the interaction of C5a 
with C5aR1 completely abrogated rH19–20-mediated effects 
on PGA formation (Figure 4), indicating C5a remains the key 
effector molecule for PGA formation even when FH cell-surface 
regulation is impaired. While the CP plays a key role in initiating 
complement activity when FH regulation is intact (25), inhibi-
tion of the CP had only an intermediate effect in the presence of 
dyresgulated FH cell surface protection compared to inhibiting 
all complement activity or C5a-C5aR1 interactions (Figure  5). 
SALO reduced the effects of rH19–20 on PGA formation and 
C5a generation by about 50% (Figure 5), as opposed to inhibiting 
properdin or all AP activity, which completely abrogate the effects 
of rH19–20 on PGA formation and C3 fragment deposition (25). 
Together, results from Figures 4 and 5 and our previous study 
(25) suggest that in the absence of FH cell-surface protection 
in TRAP-stimulated whole blood, the CP plays a limited role 
in initiating complement activity and properdin-enhanced AP 
activity that generates C5a primarily accounts for the effects of 
complement on PGA formation. Our findings support targeted 
inhibition of the AP or C5a as a potential therapeutic option 
for patients with aHUS, and suggest that some of the benefits of 
inhibiting C5 in patients with, or in a mouse model of, aHUS may 
be a result of reduced platelet/granulocyte interactions (45, 46).
Mutations in domains 19–20 that are associated with aHUS 
have variable effects on binding to C3b and heparin when meas-
ured individually (9), meaning mutations could have variable 
effects on FH binding at the platelet/granulocyte interface. When 
evaluated in TRAP-stimulated whole blood, the 14 rH19–20 
mutant constructs had differential effects on PGA formation, 
C3 fragment deposition, C5a generation, and CD11b expression 
(Figures 6 and 7). The pattern of effects of each mutant on PGA 
formation and C3 fragment deposition in TRAP-stimulated 
whole blood was similar to the pattern of effects on C3 frag-
ment deposition on platelets and neutrophils in vitro (Figures 8 
and 9). The moderate lack of correlation between C3 frag-
ment deposition on isolated platelets and isolated neutrophils 
(r = 0.56; Figure 9E) suggests a possibility of FH binding not 
only to similar ligands, but also to ligands that are specific to 
either cell. For instance, FH can bind to pentraxin 3, which is 
secreted from neutrophil secondary granules, but not found in 
platelets (47). Effects of the mutants on C3 fragment deposition 
on isolated platelets (Figures 9A,B) and on isolated neutrophils 
(Figures 9C,D) each correlated with effects of the mutants on 
PGA formation and C3 fragment deposition on the granulocyte 
population (which includes PGAs) in TRAP-stimulated whole 
blood. Collectively, this suggests that FH control of the AP 
on both platelets and neutrophils contributes to regulation of 
TRAP-mediated PGA formation. Figure 10 shows a model for 
how full-length FH (Figure 10A), WT and mutant rH19–20 that 
are used in the ex vivo assays (Figures 10B,C), and full-length 
FH with C-terminal mutations (Figure 10D) participate in PGA 
formation.
The mutations had similar effects on control of the AP on 
human erythrocytes in a study by Ferreira et al. (9), indicating 
that while the magnitude of impairment may differ between cell 
surfaces, the relative effects of each mutation remain the same. 
In addition, Hyvarinen et al. tested the effects of three mutants 
used in our study (W1183L, T1184R, and R1215Q) on control 
of AP on platelets, and found T1184R to be unimpaired in its 
ability to compete with FH on platelets, while W1183L and 
R1215Q were impaired (13). These data are in good agreement 
with our results. The mutations can thus be divided into three 
subcategories: “high impairment,” “intermediate impairment,” 
and “low impairment.” Mutants D1119G, R1182S, R1215G, and 
R1215Q represent the “high impairment” group, as they were 
the mutants most impaired relative to WT on each cell surface. 
The designer mutant K1188Q, while not tested on platelets and 
neutrophils due to limited supplies, was one of the most impaired 
on human erythrocytes (9) and in controlling PGA formation 
(Figure 6), thus it would also likely fall into this group. Mutants 
R1203S and T1184R represent the “low impairment group.” These 
mutants were unimpaired or performed even better than WT 
in each assay tested. Based on their effects on PGA formation 
(Figure 6) and on lysis of human erythrocytes (9), R1210S and 
K1230A also fall into the “low impairment” group. The remaining 
mutations are in the “intermediate impairment” group, because 
they were either (1) intermediately impaired in each assay or (2) 
their effects varied depending on the assay. For instance, S1191L/
V1197A significantly increased PGA formation (Figure 6A) and 
C3 fragment deposition on neutrophils (Figure 8B), but failed 
to significantly increase C3 fragment deposition on platelets 
(Figure 8A), relative to samples that did not receive rH19–20.
Of note, three of the four mutants in the “low impairment” 
group were the designer mutants R1203S, R1210S, and K1230A 
that were originally created to probe C3b and polyanion binding 
sites (9). Considering these mutants have not been associated 
with disease, it is not unexpected that these mutations had little 
effect in our assay. While these mutations cause differences in 
individual affinities to C3b and heparin (9), it appears that in 
a complex thromboinflammatory environment they have little 
to know effect on global FH function. The remaining designer 
mutant, K1188Q, was more impaired than the other designer 
mutants in our whole blood assay (Figure 6). This may reflect 
the location of this particular residue in the C-terminus, which 
resides in the sialic acid binding site (18), as opposed to R1203, 
R1210, and K1230 that reside outside the critical sialic acid 
contact points.
The mere location of K1188 likely does not entirely explain its 
effect on FH function. T1184 is located in the same functional site 
as K1188 in the C-terminus, a flexible region within the sialic acid 
binding site that does not make any direct contacts with the ligand 
(18). However, unlike K1188Q, T1184R was minimally impaired 
relative to WT in our assays, but has been associated with aHUS 
in genetic studies (19). The minimal effects of T1184R on FH 
function in our assays suggests T1184R may not, by itself, be a 
causative mutation for the development of aHUS and may require 
other factors such as additional complement-related mutations or 
FigUre 10 | Schematic for Factor H (FH)-mediated control of complement at the platelet/granulocyte interface. (a) Wild-type (WT) FH negatively regulates 
complement activation and platelet/granulocyte aggregate (PGA) formation. (B) The rH19–20 fragment that is used in the in vitro assays competitively inhibits the 
ability of full-length FH to regulate complement activation, resulting in increased C5a generation, CR3 expression, and thus increased PGA formation. (c) The 
rH19–20 mutants used in the assays have variable ability to inhibit full-length FH-mediated complement regulation. Compared to WT rH19–20, the mutants may 
bind poorly to cells and have less impact on full-length FH-mediated protection from complement, resulting in reduced complement activation and PGA formation. If 
the rH19–20 mutant is not affected in his ability to bind, it will effectively compete with full-length FH, similar to WT rH19–20 (depicted in B), leading to increased 
complement activation and PGA formation. (D) Atypical hemolytic uremic syndrome-associated mutations in the C-terminus of full-length FH may have variable 
ability to bind to cells and will thus result in similar or increased PLA formation as compared to WT FH. Dotted lines represent variable effect on complement 
activation on cell surfaces or variable ability to bind/compete.
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sensitivity to specific triggers to develop disease. Indeed, the rare 
genetic variant T1184R has only been reported in one sporadic 
case of aHUS while the variants D1119G and R1215G, which 
have shown to have highly impaired function, are reported to 
segregate with disease in families with high penetrance.
The crystal structures for rH19–20 engaged with C3d (17) 
and sialic acid (18) offer insights into the effects of the muta-
tions on binding to these ligands, yet there is no consensus as 
to how the structural data relates to the level of impairment on 
the cell surface. As stated, T1184 and K1188 are both within a 
region of the sialic acid binding site that is flexible but makes 
no direct contacts with sialic acid (18), but these mutants have 
drastically different effects on PGA formation and AP activity 
(Figure  6). These mutations also have dramatically different 
effects on binding to C3b and heparin; K1188Q is impaired in 
binding to both, while T1184R binds with greater affinity than 
WT to each (9). Individual affinities to either C3b or heparin as 
a contributing factor for cell surface effects are also unlikely, as 
R1182S and R1203S have nearly identical affinities for C3b and 
heparin (9), but have completely different effects on PGA forma-
tion (Figure  6). Hyvarinen et  al. showed that some mutations 
resulted in specific impairment in binding to sialic acid on cell 
surfaces (13), however, a universal mechanism for the effects of 
aHUS-related mutations on control of the AP on erythrocytes, 
platelets, and endothelial cells (cell types effected in aHUS) 
remains to be determined.
15
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The effects that aHUS-related mutations have on binding to 
polyanions other than sialic acid and heparin remain poorly 
understood. Chondroitin-4-sulfate is the primary glycosami-
noglycan (GAG) on both platelets and neutrophils (48), and 
platelets secrete high concentrations of chondroitin-4-sulfate 
into the microenvironment upon activation (23). FH binds to 
chondroitin-4-sulfate (37, 49) and Herbert et  al. demonstrated 
that rH19–20 mutants S1191L and S1191L/V1197A were 
unimpaired in binding to the related chondroitin-6-sulfate, 
among other polyanions (50). This raises the possibility that 
FH C-terminal domains may utilize GAGs in conjunction with 
C3b to bind to platelets and neutrophils, and that mutations in 
the C-terminal domains have differential effects on the ability 
of the mutants to bind and protect each cell. This has important 
implications for complement control in the vasculature, as both 
platelets and neutrophils activate the AP on their surface to aid in 
the thromboinflammatory response (12, 35). Depending on the 
mutation, AP activation could preferentially occur on platelets 
versus neutrophils, or vice versa, and patients could benefit from 
platelet- or neutrophil-targeted therapeutics. This also raises the 
possibility that mutations could be inserted into domains 19–20 
of the developing therapeutic, mini-FH (51, 52), in order to target 
it to specific cell types. For instance, T1184R binds very strongly 
to platelets and neutrophils (Figure 8), thus a T1184R-mini-FH 
construct may enhance regulation of AP activity specifically on 
platelets and neutrophils at thromboinflammatory locations, 
thus limiting its retention at other locations in the body. More 
detailed studies into the effects of each mutation on cell- and 
tissue-specific binding are necessary to evaluate this possibility.
Our data suggest that in patients suffering from aHUS who 
have mutations in the “high impairment” group, increased PGA 
formation could contribute to excessive thrombosis. These 
patients may benefit from anti-inflammatory medications, 
including anti-complement therapeutics, to decrease thrombo-
inflammatory effects of activated neutrophils in the vasculature, 
although clinical studies should be conducted to determine the 
extent of PGA formation in these patients. Because the tubular 
epithelium has a limited capacity to restrain complement acti-
vation (53), mutations in the “low impairment” are likely still 
impaired in their ability to protect the renal tubular epithelium. 
It is also possible that some aHUS-related mutations prevent 
FH oligomerization on the tubular epithelium (28). Based on 
the critical role of FH in protecting the tubular epithelium, FH 
oligomerization could be an essential step in providing effective 
control of the AP. Effects of aHUS-related mutations on FH 
oligomerization are unknown.
In conclusion, our data indicate FH C-terminal domains 19 and 
20 are critical for controlling PGA formation and AP activation 
on platelets and neutrophils and that mutations in the C-terminal 
domains have differential effects on PGA formation. Our data 
have important implications for understanding the pathophysi-
ologic mechanisms involved in aHUS and diseases characterized 
by increased PGA formation, and suggests that future studies 
should consider the contribution of platelet/granulocyte interac-
tions in the manifestation of aHUS.
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